...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma
【24h】

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma

机译:慢性和闷烧型成人T细胞白血病淋巴瘤的预后指数

获取原文
获取原文并翻译 | 示例
           

摘要

Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log(10) (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P<.05 in training samples. A multivariate analysis was performed on these factors, and only log(10) (sIL-2R) was identified as an independent prognostic factor in training samples. Using a regression coefficient of this variable, a prognostic model was formulated to identify different levels of risk: indolent ATL-PI (iATL-PI) 51.513 log(10) (sIL-2R [U/mL]). The values calculated by iATL-PI were divided into 3 groups using a quartile point. In the validation sample, median survival times(MSTs) were 1.6 years, 5.5 years, and not reached for patients in the high-, intermediate-, and low-risk groups, respectively (P<.0001). To make the scoring system clinically practicable, we simplified iATL-PI according to trichotomizing sIL-2R at 1000 and 6000 U/mL, using a quartile point. Patients with more than 6000 U/mL sIL-2R were categorized into the high-risk group, less than and equal to 1000 U/mL into the low-risk group, and the others into the intermediate-risk group, and MSTs were 1.6 years, not reached, and 5.5 years, respectively (P<.0001). iATL-PIhas potential as a novel tool for a risk-adapted therapeutic approach.
机译:成人T细胞白血病 - 淋巴瘤(ATL)分为4个临床亚型:急性,淋巴瘤,慢性和闷烧。本研究的目的是为慢性和闷烧ATL开发一种新的预后指数(PI)。我们在ATL患者进行了全国性的回顾性调查,在此分析中使用了248个完全合格的个体。在单变量分析,性别,性能状态,对数(10)(可溶性白细胞介素-2受体[SIL-2R]),中性粒细胞计数和淋巴结病,显示出训练样品中P <.05的值。对这些因素进行多变量分析,并且只有数值(10)(SIL-2R)被鉴定为训练样本的独立预后因素。使用该变量的回归系数,配制了预后模型以鉴定不同程度的风险:惰性ATL-PI(IATL-PI)51.513 LOG(10)(SIL-2R [U / ML])。使用四分位数分为3组由IATL-PI计算的值。在验证样本中,中位生存时间(MSTS)分别为1.6岁,5.5岁,分别为高,中间和低风险群体的患者达到(P <.0001)。为了使得分系统在临床上切实可行,我们使用四分位数的点,通过在1000和6000 u / ml时简化IATL-PI。患有6000多种U / ML SIL-2R的患者分为高风险组,小于和等于1000 u / ml进入低风险组,其他人进入中间风险组,MSTS为1.6多年来,未达到和5岁(P <.0001)。 IATL-PIHAS作为风险适应的治疗方法的新型工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号